MeiraGTx FY2025 license revenue rises to $75 million; net loss per share narrows to $1.42

Reuters03-26
MeiraGTx FY2025 license revenue rises to $75 million; net loss per share narrows to $1.42
  • MeiraGTx published a press release reporting fourth-quarter and full-year 2025 financial and operational results and a corporate update.
  • Net loss attributable to ordinary shareholders was USD 114.2 million, or USD 1.42 per share, compared with a narrower loss in the prior year.
  • Total revenue was USD 81.39 million, including service revenue of USD 6.4 million (down 80.77%) and license revenue of USD 75.0 million.
  • Research and development expense was USD 129.62 million (up 8.45%), which MeiraGTx attributed mainly to higher manufacturing costs and increased activity across clinical and preclinical programs.
  • Cash, cash equivalents and restricted cash were USD 68.2 million at Dec. 31, 2025 (down 35.48%), and the company said it expects existing capital to fund operations into the second half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MeiraGTx Holdings plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603260800PRIMZONEFULLFEED9679097) on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment